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ABSTRACT
Diabetes mellitus is a metabolic disease that is caused either by the decrease of insulin secretion from
pancreatic β cells or the insensitivity of target cells against insulin. High glucose levels (hyperglycemia condition)
can trigger the formation of free radicals, the main cause of diabetes micro and macrovascular complications. The
formation of free radicals and AGE (advanced glycation end-products) is assumed to became the key factor in the
decline of granulocyte cell production as well as the disruption of these cells functional activity. The purpose of
this research was to determine the role of VipAlbumin® in inhibiting the adverse effects of increased blood glucose
levels, which highly influence the production of granulocyte. This study was divided into in vitro and in vivo
stage. BALB/C mice were used as experimental animals at in vivo stage and induced to undergo diabetes through
100 mg/kg BW streptozotocin (STZ) injection at the age of 5 days. VipAlbumin® administered orally for 14 days,
which began when mice reached the age of 14 weeks. The administration of VipAlbumin® divided into 3 doses
i.e. 0,01664 mg/gr BW (1st dose), 0,416 mg/gr BW (2nd dose), and 10,4 mg/gr BW (3rd dose). The further step was
a flowcytometric analysis to see the development of granulocyte cells relative amount, which were isolated from
the bone marrow. The result of this analysis shows that VipAlbumin® administration, particularly at the 2nd and
3rd dose, were able to modulate granulocyte cells development in the bone marrow.
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Diabetes mellitus, according to American Diabetes
Association  [1],  is  classified  as  a  metabolic  disease
characterized  by  hyperglycemia  or  high  blood  sugar
levels over a prolonged period. This disease is due to
the defects in insulin secretion, insulin mechanism, or
both. The significant influences in the pathogenesis of
diabetes mellitus come from Reactive Oxygen Species
(ROS). These free radicals are formed through Non-
Enzymatic glycosylation, mitochondrial electron trans-
port chain dysfunction, or activation of hexosamine in-
duced by hyperglycemia [2]. In a case of type 2 dia-
betes, ROS is one of the main factors in the develop-
ment  of  micro  and  macrovascular  complications.  It
breaks transmission path between insulin receptor and
glucose  transport  system,  inducing  the  insulin  resis-
tance and inactivation of two essential anti-atheroscle-
rosis enzymes: endothelial nitrite oxide and prostacy-
clin synthase [3,4,5].
Besides playing an important role in the formation
of advanced glycation end-products (AGE), ROS also
mediates the effects of AGE upon target issues. A con-
nection between clinical complication of diabetes melli-
tus and oxidative stress is involved in high-dose AGE
formation.  The glycation product  (Amadori),  formed
by  a  reaction  between  aldehyde  and  protein  amino
group, can be oxidized (i.e. by reactive oxygen species)
into AGE formation. The biochemical process of this
glycation is gradually increased in diabetic patients, af-
fected by both hyperglycemia, oxidative stress and the
increase of fatty acid [5].
In patients with diabetes mellitus, there is a decline
in mobilization and chemotaxis  abilities  of  mononu-
clear and polymorphonuclear/PMN (i.e. neutrophil) in
which it decreases the phagocytosis capability. There is
a negative correlation between phagocytosis and high
levels of blood sugar in the diabetic patients [6]. 
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To determine the effect of hyperglycemia towards
both developments and activities of granulocytes (espe-
cially neutrophil), mice model of diabetes mellitus are
used. The mice are injected with streptozotocin or STZ
(2-deoxy-2-(3-methyl-3-nitrosourea), which is a widely
used antibiotic formed by Streptomyces achromogenes.
According to Tesch & Allen [7] and Szkudelski [8], the
toxicity  mechanism of  STZ starts  when  it  infiltrates
into  β cells through GLUT 2 transporter and kills  β
cells  due  to  DNA fragmentation  associated  with  ni-
trosourea.
The decrease in insulin secretion by β cells as well
as  the  increase  of  blood  sugar  level  triggering  both
ROS and AGE formations are assumed as the key fac-
tor  of  granulocytes  deficiency.  This  research  used  a
supplement derived from albumin extract of snakehead
murrel (Channa striatus) named VipAlbumin®, which
allegedly  has  better  antioxidants.  Several  researchers
show that albumin has strong antioxidants, free radi-
cals  purification through redox cycle in thiol (Cys34)
[9],  and  metal  ion binding  [10,11,12].  VipAlbumin®
administration is expected to repair  β cells  ability in
excreting insulin and binding various ROS formed by
hyperglycemia, which will later affect the production of
granulocytes.
This research was conducted from November 2014
to May 2015 in Animal Physiology Laboratory of Biol-
ogy Department, Faculty of Mathematics and Natural
Sciences, University of Brawijaya, Malang.
Research Design
This research was experimental research, which ap-
plies  manipulative  treatments  and  observes  the
emerged effects of the treatments by tightly controlling
on polluters. In vitro procedure contains 5 treatments
with  5  repetitions:  negative  control,  positive  control
(with  EPO/erythropoietin  treatment),  and  VipAlbu-
min®1st dose, 2nd dose, and 3rd dose. Moreover, in
vivo experiment contains 5 treatments: negative control
(healthy  mice  without  any  VipAlbumin® administra-
tion), positive control (diabetic mice without VipAlbu-
min® administration), 1st dose, 2nd dose, and 3rd dose of
VipAlbumin®, in which each treatment consists of 5
repetitions.
In Vitro Procedures
Fabrication of VipAlbumin® Stock
The  initial  concentration  was  33333.3  µg/ml  de-
rived from dissolution of 33.3 mg VipAlbumin® in 1
ml medium. The third dose with the concentration of
3333.3 µg/ml was derived from 10 times stock dissolu-
tion. This dose was diluted again by 100 times to form
the second dose with the concentration of 33.3 µg/ml.
Last,  the  first  dose  with  the  concentration  of  0.33
µg/ml was derived from diluting the second dose by
100 times.  The second  dose  is  a  standard  treatment
based on assumption that  healthy man with average
weight (± 60 kg) can consume VipAlbumin® 2 g per
day.
Fabrication of Culture Medium
All  procedures  of  culture  medium  manufacture
were conducted in Laminar Air Flow (LAF) to prevent
contamination. The medium used in this research was
RPMI 1640 with additional Fetal Bovine Serum (FBS)
10%, 1% Penicillin and Streptomycin, and 1µg 2-Mer-
captoethanol (2-ME) in 10 ml medium. The medium
was  also  given LPS stimulant  (lipopolysaccharide,  to
stimulate lymphocytes from bone marrow) 2 µg in 1
ml medium. The usable medium was filtered by Milli-
pore  0.20  µm.  The  treatment  of  positive  control  by
EPO/erythropoietin administration was done by mix-
ing 1µl EPO and 99µl culture media. The suspension
formed was then taken by 1µl to be mixed with 1 ml
media and used in the culture process.
Cell Isolation from Bone Marrow
Mice was dislocated on the neck, cleaned with alco-
hol  and  dissected.  The  feet  were  taken  and  cleaned
from  fat.  Afterward,  the  femur  and  tibia  part  were
flushed with PBS at one end by using 1 ml syringe so
that cells would come out from another end. The sus-
pension of cells and PBS gained were transferred into
propylene  tube  to  be  centrifuged  at  2.500  rpm,
temperature 10° C, for 5 minutes. Last, the supernatant
was eliminated, and the pellet formed was resuspended
in 1 ml medium.
Cells Calculation
The  suspension  of  cells  from  bone  marrow  was
taken 5µl, accommodated in a microtube and added 95
µl of Evans blue (dilution of 20 times) which then was
pipetted for homogenization. Afterward, cells were cal-
culated by hemocytometer under the microscope. The
number of cells was then formulated as follows:
Σ Cells = Σ counted cells x 5 x diluent factor x 104
cells/ml
Planting and harvesting the Cell Culture
3 million cells per ml (through the hemocytometer
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calculation) were added to each medium with different
treatments and homogenized. Next, cells were planted
in plate culture 48 well, in which each well contained 1
ml cell suspension and medium. Cells were incubated
in incubator CO2 5%, temperature 37°C for five days.
After  the incubation,  cells  were  harvested from each
well (based on treatment group), by pipetting cell sus-
pension  and  medium  and  moved  it  into  propylene
tube. 1 ml PBS was added to the wells to take the rest
of  cell  suspension  remained.  Moreover,  it  was  cen-
trifuged at  speed 2.500 rpm temperature 10°C for 5
minutes. Formed pellet  was resuspended in PBS and
stained with antibodies.
Cells Staining with Antibodies
Bone marrow cell  suspension gained from culture
was accommodated in a micro tube and centrifuged at
speed  2.500  rpm,  temperature  10°C  for  5  minutes.
Formed pellet was then added with a 1µl antibody that
has been diluted with 50 µl PBS and 10% FBS, and in-
cubated  in  the  icebox  with  temperature  4°C  for  20
minutes. Staining combination used was FITC-conju-
gated rat anti-mouse Gr-1.
Running Flow cytometry
Incubated cells derived from antibody staining were
added with 300-500 µl PBS, then transferred into a cu-
vette and processed in flow cytometry machine.  The
program was  set  as  ’acquisition’,  and gating  process
was done based on cell types that would be identified
and analyzed.
In Vivo Procedures
Induction of Diabetes Mellitus in Mice
Healthy neonatal mice aged five days was induced
as the model of diabetes mellitus through STZ injec-
tion  intraperitoneally,  at  a  dose  of  100  mg/kg  body
weight. Being assumed that each mouse has weight ±
2.5 g, the STZ injection should reach 50 mL, derived
from stock made by mixing 0.005 grams of STZ pow-
der with 1 ml citrate buffer.  Mice that had been in-
jected was allowed to grow in the chamber, being fed
and drink. The replacement of the husk was routinely
done. After four weeks, the blood glucose level of mice
was measured by glucometer. The high blood glucose
level, reaching more than 200 mg/dl showed that the
mice had been successfully induced diabetes mellitus.
Oral Administration of VipAlbumin®
Mice that has positively diagnosed as diabetes melli-
tus was then given VipAlbumin® orally, divided into 4
dose  treatments:  0  mg/gr  BW  (positive  control);
0.01664  mg/gr  BW (1st dose);  0.416  mg/g  BW (2nd
dose);  10.4  mg/g BW (3rd doses).  Doses  above were
obtained from the conversion of albumin dose for 1-
kg-weight  man,  which is  assumed to  have  a  normal
weight 60 kg, i.e. 33.3 mg/kg. The VipAlbumin® ad-
ministration was carried out for 14 days. The measure-
ment of blood glucose level was regularly done once in
every three days, to determine whether the administra-
tion of VipAlbumin® has  influenced in reducing the
blood glucose level.
Cells Isolation from Bone Marrow and Calculation
Mice was dislocated on the neck, cleaned with alco-
hol and dissected. Part of femur and tibia removed and
cleaned from fat,  then flushed with PBS at  one end
(using a  1  ml  syringe).  The suspension of  cells  was
then transferred into propylene tube to be centrifuged
at a speed of 2500 rpm, temperature 10°C, for 5 min-
utes. Formed pellet was resuspended in 1 ml PBS. The
result of re-suspension was taken 5µl,  accommodated
in a microtube, and added with 95 µl of Evans blue (di-
lution of 20 times), which then was pipetted for ho-
mogenization. Cells were then calculated by hemocy-
tometer under the microscope.
Cells  staining  with  antibodies  and  Running
Flowcytometry
The cell suspension of bone marrow (250 µl) was
accommodated in a microtube and centrifuged at 2.500
rpm, temperature 10°C for 5 minutes. The formed pel-
let was then added with a 1µl antibody that has been
diluted with 50 µl PBS and 10% FBS, and incubated in
4°C icebox for 20 minutes. Staining combination used
was FITC-conjugated  rat  anti-mouse  Gr-1.  Incubated
cells derived from antibodies staining were added with
300-500  µl  PBS,  then  transferred  into  a  cuvette  and
processed in flowcytometry machine. The program was
set as ’acquisition’, and gating process was done based
on cell types that would be identified and analyzed.
Statistical Analysis
Cell  profiles  obtained  from  flowcytometry  were
analyzed using BD Cellquest Pro™ software. The data
were collected and analyzed statistically with SPSS v16
for Windows. The analysis is one-way ANOVA para-
metric analysis with p = 0.05%, by applying Turkey ad-
vanced test. 
Flowcytometric  Analysis  of  Granulocytes  Relative
JTLS | J. Trop. Life. Science 135 Volume 5 | Number 3 | September | 2015
RESULTS AND DISCUSSION
Andi Rizki Adi Pradana et al., 2015
Amount In Vitro
From the data above, the highest granulocytes rela-
tive amount increase was after the third dose of VipAl-
bumin® (3333.3 µg/ml media). On the positive control
with erythropoietin administration, despite being capa-
ble  of  stimulating  the  development  of  granulocytes
which is better than the negative control, but the result
was  not  significant.  Meanwhile,  the other two treat-
ments,  i.e.  1st dose  (0.33  µg/ml)  and  2nd dose  (33.3
µg/ml) were not different in terms of triggering the de-
velopment  of  granulocytes  compared  to the  negative
control. 
The diagram above measures the ratio of blood glu-
cose level in mice, which was done once in every three
days  and  started  when the  mice  were  four-week-old
(calculated from 5 days after birth). The graphic shows
that mice with highest glucose level is a positive con-
trol,  which was successfully induced to undergo dia-
betes mellitus through STZ without any VipAlbumin®
administration.  In  the  first  dose  of  VipAlbumin®
(0.01664 mg/gr BW), an increase of blood glucose level
was directly proportional to age, although it was still
significantly lower than the positive control. Blood glu-
cose  levels  in  VipAlbumin® treatments  second  dose
(0.416  mg/g  BW)  and  third  dose  (10.4  mg/g  BW)
seemed fluctuate, possibly decreased or increased while
being measured on different days. In the final days of
measurement,  the  third  dose  of  VipAlbumin® treat-
ment showed a significant reduction in blood glucose
level, although the decline had not reached the state of
normal mice (negative control).
Flowcytometric  Analysis  of  Granulocytes  Relative
Amount In Vivo
The results of flowcytometric analysis of the devel-
opment of granulocytes at in vivo treatment showed a
significant  difference  between  normal  mice  (negative
control)  and  diabetic  mice  (positive  control).  From
three  different  VipAlbumin® treatments,  2nd dose
(0.416 mg/g BW) and 3rd dose (10.4 mg/g BW) showed
a significantly different increase in granulocytes growth
compared to the positive control. The remaining dose
of VipAlbumin®(1st dose, 0.01664 mg/gr BW) did not
show any increase in the relative amount of granulo-
cytes and was not considerably different from the nega-
tive control treatment.
From the graphic above, it can be seen the signifi-
cant  differences  between  normal  mice  and  diabetic
mice  in  terms  of  its  ability  to  develop  granulocytes.
Hyperglycemia triggered by the action of STZ is esti-
mated to be the leading cause of the decline in the rela-
tive number of granulocytes. Chronic diseases such as
type 2 diabetes, insulin resistance caused by age, nutri-
tional factors, and lifestyle have a significant effect on
PMN function. Like the record, the risk of infectious
diseases are two to four times higher in diabetic pa-
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Figure  1.  Flowcytometric  analysis  of  Gr-1 profile  in  vitro;  (a)
negative  control,  (b)  erythropoietin  treatment,  (c)
VipAlbumin® 1st dose,  (d)  VipAlbumin®2nd dose,  (e)
VipAlbumin®3rd dose.  Bone  marrow  cell  suspension
gained  from culture  process  then  added  with  a  1µl
antibody that  has  been diluted with 50 µl  PBS and
10% FBS. Staining combination used was FITC-conju-
gated rat anti-mouse Gr-1. The 3rd dose of VipAlbu-
min® showed the highest increase of granulocyte rela-
tive amount (%) compared with negative control.
Figure  2. Gr-1 relative amount in culture condition (in vitro).
Cell  profiles  obtained  from  flow  cytometry  were
analyzed using BD Cellquest Pro™ software. The data
were collected and analyzed statistically with SPSS v16
for  Windows.  VipAlbumin® treatment  third  dose
showed a significant  increase in  granulocyte  relative
amount  compared  to  the  positive  control  (*signifi-
cantly different, p<0,05).
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tients [13]. ROS production by neutrophils in diabetic
patients  are  increased;  but  on  another  hand,  neu-
trophils also increases apoptosis induction and signifi-
cantly decreases chemotactic response. It is known that
the amount of  circulated  pro-inflammatory  cytokines
in blood flow has been increased in diabetic patients
and was considerably suspected that dysfunction occur-
ring in neutrophils contributes to the rise of suscepti-
bility  towards  infections  in  these  patients.  Hyper-
glycemia or the presence of AGE can trigger the activa-
tion of neutrophils, and it can be proven through an
increase  in  alkaline  phosphatase  produced  by  neu-
trophils [14]. Several studies have showed an increased
release of TNF-α, IL-8, and IL-6 [14,15] and decreased
secretion of  granular  proteins  by  neutrophils  in  dia-
betic patients [16,17].
According to Rifa’i and Widodo [18], regulatory T
cells, especially in the CD4+CD25+ population, have an
important role in maintaining normal homeostasis in
many degenerative diseases including diabetes mellitus.
Some research  was  suggesting  that  the  activation of
autoreactive T cells  in the diabetic individual  can be
conducted from self-antigen recognition by cytotoxic T
cells and Th1 cells. This activation later triggers the ac-
tivation of other cells in the immune system to stimu-
late  systemic  homeostasis  disorders  [19,20,21,22].Re-
search conducted by Rifa’i [23] by using mouse model
of autoimmune disease (CD122-deficient mice) shows
that the transfer of 2 x 106 CD4+CD25+ cells can en-
hance  TER-119+ cells  (erythroid-lineage)  number  in-
crease while suppress the activity of granulocytic Gr-1+
cells to recognize self-antigen. This result supports the
role  of  regulatory  T cells  as  a principal  regulator of
body homeostasis, by normalizing leukocyte number in
the peripheral blood and prevent any harmful conse-
quences.
As we all know, neutrophils as the biggest fraction
of granulocytic cells, play a significant role in the host
inflammatory response towards infection. According to
Mowatt & Baum [24], there is an important decrease
in neutrophil chemotactic activity in diabetic patients
compared  to  normal  controls.  Several  studies  have
shown indications of a decline in bactericidal activity
[25], interference in the phagocytosis ability and a re-
duction  of  lysosomal  enzymes  release  [26],  and  de-
creased production of ROS [27] by neutrophils in dia-
betic patients. Moreover, a decline in the number of
phagocytic leukocytes and bactericidal activity correlate
with an increase in blood sugar levels [28]. Studies us-
ing diabetic mice have also showed a decrease in neu-
trophil migration [29,30,31,32], phagocytic activity [33]
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Figure 3.  The comparison of blood glucose levels in each treat-
ment.  100 mg/kg BW STZ was  injected intraperi-
toneally to 5-day old healthy mice. After four weeks,
the blood glucose level of mice was measured by glu-
cometer and regularly done once in every three days
after that, to determine whether the administration
VipAlbumin® has  influence  in  reducing  the  blood
glucose level. Blood glucose level seemed fluctuate in
the  second  and  third  dose  of  VipAlbumin® treat-
ments. In the last six days of measurement, an only
third  dose  of  VipAlbumin® showed  a  significant
blood glucose decrease.
                                  
Figure 4.  Flowcytometric  analysis  of Gr-1 profile in vivo;  (a)
negative  control,  (b)  positive  control,  (c)  VipAlbu-
min® 1st dose,  (d)  VipAlbumin® 2nd dose,  (e)
VipAlbumin® 3rd dose. Mice was dislocated, part of its
femur and tibia were removed, then flushed with PBS
to  get  the  cell  suspension.  This  suspension  then
centrifuged and processed in flow cytometry machine
thereafter.  Staining  combination  used  was  FITC-
conjugated  rat  anti-mouse  Gr-1.  There  was  a
significant  decrease  in  granulocyte  relative  amount
(%) of positive control compared to negative control.
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and  the  production of  hydrogen peroxide  [34].  Fur-
thermore, the efforts to reduce blood sugar levels by
administering insulin to diabetic rats [34] are reported
to have a correlation with a significant increase in the
capacity of phagocytosis by neutrophils. Some antimi-
crobial proteins produced by neutrophils such as lacto-
ferrin,  protein  enhancer  for  permeability/bactericidal
and  α-defensins are proportionally decreased with re-
spect to the development of insulin resistance and dia-
betes. The reduced concentration of these proteins is in
line  with  the  low capacity of  antimicrobials  by  neu-
trophils in diabetic subjects. Furthermore, one of these
proteins (lactoferrin) is known to have a direct influ-
ence on the metabolism, enhance the action of insulin,
increase the activity of AMP kinase protein, and trigger
weight loss [35,36].
The graphic above also shows a significant rise in
the relative amount of granulocytes in the second dose
and  third  dose  treatment,  compared  to  the  positive
control. This increase can even match the correspond-
ing  number  of  granulocytes  in  the  negative  control,
which is normal mice. VipAlbumin® role in inhibiting
the  effect  of  free  radicals/ROS  caused  by  hyper-
glycemia condition is assumed to be an important fac-
tor of an increase in the relative amount of granulo-
cytes. Albumin is an important extracellular source for
reduced sulfhydryl cluster, which is in the form of a
single cysteine residue at the 31st position in the mole-
cule. This sulfhydryl group, which is referred as thiol,
is the primary scavenger of reactive oxygen and nitro-
gen species, particularly superoxide and hydroxyl per-
oxynitrite. Albumin may also limit the production of
reactive species through free copper Cu2+ bond, which
is an ion that is known to play a significant role in ac-
celerating the production of free radicals [37]. Albumin
itself  is  the  owner  of  the  majority  of  total  thiol  in
plasma so that albumin can affect  the redox equilib-
rium and has an important implication in indicating
various critical diseases such as capillary permeability,
rheology  change,  cell-signaling  processes,  anti-hemo-
static effects, drug metabolism and transport processes
[38].
The decreased amount of free radicals and  β cells
repair will trigger the improvement of insulin produc-
tion, which is very influential on the development of
granulocytes, especially neutrophils. Some studies sug-
gest that insulin has a strong influence on the regula-
tion of the functional activity of immune cells [39,40].
The  essential  action of  insulin  on the  PMN activity
may be seen as the body provides global protection for
the support of the primary immune response against
foreign  antigens  entering  through  food  intake  [41].
Walrand et al. [42] states that the change in the PMN
function in diabetic subjects can be improved through
the hyperglycemia control by using insulin. Although
PMN does not require insulin to take up glucose, both
glucose and glycogen metabolism in PMN depends on
insulin activity. Also, expression of the insulin receptor
is known to have good correlation with PMN chemo-
taxis in young and elderly subjects, after insulin treat-
ment. An antimicrobial protein produced by PMN is
considerably impaired due to the presence of insulin
resistance in older subjects [42].
In  in vitro  procedure, the third dose of VipAlbu-
min® administration can increase granulocyte relative
amount and significantly different from negative con-
trol.  The  administration  of  VipAlbumin® at  in  vivo
procedure,  particularly  on  the  2nd dose  (0.416  mg/g
BW) and  3rd dose (10.4 mg/g BW), can also signifi-
cantly increase granulocytes relative amount compared
to the positive control.
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